Company profile for Atossa Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Atossa Therapeutics is a clinical-stage biopharmaceutical company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. We believe our innovative therapies and delivery methods can transform breast cancer treatment– with the goals of preventing breast cancer from developing in the first place, to increasing the odds of surviving for those who do develop this deadly dis...
Atossa Therapeutics is a clinical-stage biopharmaceutical company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. We believe our innovative therapies and delivery methods can transform breast cancer treatment– with the goals of preventing breast cancer from developing in the first place, to increasing the odds of surviving for those who do develop this deadly disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1616 Eastlake Ave E, Suite 201, Seattle, WA 98102
Telephone
Telephone
866-893-4927
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/atossa-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update-302612557.html

PR NEWSWIRE
12 Nov 2025

https://www.prnewswire.com/news-releases/atossa-therapeutics-highlights-progress-in-recast-dcis-platform-trial-at-early-detection-research-conference-laura-esserman-md-mba-to-discuss-active-surveillance-strategy-and-novel-endocrine-agents-302589184.html

PR NEWSWIRE
21 Oct 2025

https://www.prnewswire.com/news-releases/atossa-advances-global-patent-strategy-for-z-endoxifen-with-new-protection-in-israel-and-ongoing-renewals-302581338.html

PR NEWSWIRE
13 Oct 2025

https://www.prnewswire.com/news-releases/atossa-therapeutics-streamlines-evangeline-breast-cancer-clinical-trial-to-prioritize-for-2026-nda-enabling-activities-302575551.html

PR NEWSWIRE
06 Oct 2025

https://www.prnewswire.com/news-releases/atossa-therapeutics-names-janet-r-rea-msph-as-senior-vice-president-rd-to-accelerate-z-endoxifen-toward-key-regulatory-milestones-302572041.html

PR NEWSWIRE
01 Oct 2025

https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-regulatory-strategy-aimed-at-accelerating-development-of-low-dose-z-endoxifen-for-breast-cancer-risk-reduction-302548910.html

PR NEWSWIRE
08 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty